IRIS
Cento, Valeria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.461
EU - Europa 520
AS - Asia 114
AF - Africa 75
SA - Sud America 2
Totale 2.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.452
FI - Finlandia 177
IE - Irlanda 140
CN - Cina 96
NG - Nigeria 59
SE - Svezia 46
DE - Germania 39
FR - Francia 35
NL - Olanda 26
BE - Belgio 15
IN - India 15
IT - Italia 14
ET - Etiopia 12
GB - Regno Unito 12
PA - Panama 7
RU - Federazione Russa 6
CM - Camerun 4
MD - Moldavia 3
CA - Canada 2
CO - Colombia 2
IL - Israele 2
AT - Austria 1
BG - Bulgaria 1
EE - Estonia 1
GR - Grecia 1
HR - Croazia 1
JP - Giappone 1
NO - Norvegia 1
PT - Portogallo 1
Totale 2.172
Salva come PNG Salva come JPEG
Città #
Chandler 399
Helsinki 177
Ashburn 159
Dublin 140
Boardman 117
New York 98
Shanghai 88
Lawrence 72
Princeton 72
Benin City 59
Paris 35
Los Angeles 28
Amsterdam 26
Pune 15
Brussels 13
Wilmington 13
London 11
Addis Ababa 8
Ann Arbor 7
Phoenix 7
Moscow 6
Cagliari 4
Roslindale 4
Chisinau 3
Leawood 3
Milan 3
San Mateo 3
Baltimore 2
Boston 2
Ciney 2
Falkenstein 2
Foggia 2
Gorizia 2
Medellín 2
Monmouth Junction 2
Nanjing 2
Trieste 2
Woodbridge 2
Andover 1
Athens 1
Buea 1
Denver 1
Eden Prairie 1
Fairfield 1
Frankfurt am Main 1
Limbe 1
Lisbon 1
Oslo 1
Potomac 1
Rome 1
Seattle 1
Sofia 1
Stockholm 1
Tallinn 1
Tappahannock 1
Tel Aviv 1
Tokyo 1
Toronto 1
Vienna 1
Washington 1
Zagreb 1
Totale 1.615
Salva come PNG Salva come JPEG
Nome #
Real life experiences in HCV management in 2018 65
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 43
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures 42
A boceprevir failure in a patient infected with HCV genotype 1g: importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy 39
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 34
Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 34
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs 32
Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model 32
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 32
Back to the future (of common respiratory viruses) 31
Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon 31
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 31
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 30
Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy 30
Biotech innovations in the prevention of respiratory infectious diseases 30
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 29
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 29
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing 29
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 29
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals 29
Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality 28
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 28
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 27
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 27
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 27
Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents 27
Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions 27
Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR? 27
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 26
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 26
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 26
Resistance to direct-acting antiviral agents: clinical utility and significance 26
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 26
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 25
In vivo acquisition and risk of inter-species spread of bla KPC-3-plasmid from Klebsiella pneumoniae to Serratia marcescens in the lower respiratory tract 25
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 25
Human papillomaviruses 53 and 66: clinical aspects and genetic analysis 24
Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology 24
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 23
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 23
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 23
Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution 22
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life 22
Prolongation of incubation time improves clinical diagnosis of Mycobacterium xenopi infection and allows susceptibility testing of mycobacterial strains against multiple antibiotics 22
Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype 22
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era 22
Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users 21
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 21
The use of human immunodeficiency virus resistance tests in clinical practice 21
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 21
Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study 20
Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients 20
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 20
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 20
The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C 19
Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience 19
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 19
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 19
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 18
Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine 17
Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric Population 16
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 16
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 15
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 15
CLINICAL RELEVANCE OF NEXT GENERATION SEQUENCING ON BASELINE DETECTION OF MINORITY RESISTANCE ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE INHIBITORS 15
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 15
KEY GENETIC SIGNATURES IN THE WHOLE pre-S1/Pre-S2/S GENE CORRELATE WITH HBV-INDUCED CARCINOGENESIS BY AFFECTING HBsAg SECRETION AND RELEASE 14
KEY PATTERNS OF HBsAg MUTATIONS CORRELATE WITH MECHANISMS UNDERLYING LEVELS OF SERUM HBV DNA 14
CLINICAL RELEVANCE OF ACCURATE HCV GENOTYPE AND SUBTYPE ASSIGNMENT BY NS3/NS5A/NS5B DIRECT SEQUENCING IN THE ERA OF NEW DIRECT ACTING ANTIVIRAL AGENTS 14
High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction 13
KEY PATTERNS OF HBX AND PRE-S1/S2 MUTATIONS ARE INVOLVED IN MECHANISMS UNDERLYING HBV-INDUCED HEPATOCELLULAR CARCINOMA IN VIVO 12
BIPHASIC KINETICS OF HCV-RNA DECAY IS ACCOMPANIED BY AN EVEN FASTER AMINOTRANSFERASES NORMALIZATION IN ALL-DAA TREATED CIRRHOTIC PATIENTS: A DIFFERENT SCENARIO FROM INTERFERON-BASED THERAPIES 12
Key genetic markers in the full-length HBsAg gene correlate with HBV-driven carcinogenesis by affecting HBsAg secretion and release 12
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 12
Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluatioN in health Care workErs 12
CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR 11
HCV GENOTYPES HAVE DIFFERENT GENETIC BARRIERS IN THE GENERATION OF RESISTANCE MUTATIONS TO PROTEASE INHIBITORS IN ADVANCED CLINICAL DEVELOPMENT 11
Biphasic kinetics of HCV-RNA decay and quasispecies evolution during DAA-treatment are associated with risk of virological failure 11
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 11
Viral Respiratory Infections: New Tools for a Rapid Diagnosis 11
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 11
DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV QUANTIFICATION WITHIN BLOOD AND LIVER SAMPLES (TUMORAL AND NON TUMORAL TISSUES) OF HCC/TRANSPLANTED PATIENTS 10
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 10
Early detection of NS3-resistance in HCV patients with advanced disease treated with BOC/TVR-based therapy: analysis by population- and ultra-deep sequencing 10
Clinical usefulness of HCV sequencing on clinical samples with different HCV-RNA levels 10
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 10
THE LOWEST X4 GENO2PHENO-FALSE POSITIVE RATE IS ASSOCIATED WITH GREATER CD4-DEPLETION 9
ROLE OF CIRCULATING SURVIVIN-IGM IMMUNOCOMPLEXES IN PATIENTS AFFECTED BY LIVER DISEASES 9
THE GENOTYPIC FALSE POSITIVE RATE DETERMINED BY POPULATION V3-SEQUENCING CAN PREDICT THE BURDEN OF X4 QUASISPECIES DETECTED BY PYROSEQUENCING 9
CLINICAL RELEVANCE OF BASELINE/EARLY DETECTION AND PERSISTENCE OF RESISTANT ASSOCIATED VARIANTS IN HCV-1 PATIENTS TREATED WITH PROTEASE-INHIBITORS ASSESSED BY ULTRA-DEEP SEQUENCING 9
Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies 9
CHARACTERISTICS OF LAMIVUDINE RESISTANCE PROFILES IN HBV REVERSE TRANSCRIPTASE FROM A NATIONAL COLLABORATIVE STUDY OF HIV plus HBV INFECTED INDIVIDUALS ON LONG-EXPOSURE TO LAMIVUDINE INCLUDING REGIMENS 9
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 9
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety 9
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 9
NS3-resistance in advanced HCV patients treated with BOC/TRV-based therapy: impact on virological failure of baseline and early time points 8
DIFFERENT PREVALENCE OF HCV RESISTANCE AND HCV RNA QUANTIFICATION WITHIN TUMORAL AND NON TUMORAL LIVER TISSUES IN HCC/TRANSPLANTED PATIENTS 8
LOW BURDEN OF DRUG-RESISTANT HBV STRAINS IN ANTI-HBV DRUG-EXPERIENCED AND NAIVE PATIENTS 8
Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy 8
VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT 8
Totale 2.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.416
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.416
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 7 6 2 5 2 1 0
2021/2022104 0 1 0 3 1 0 1 2 6 4 77 9
2022/20231.183 149 15 97 120 79 103 0 129 220 101 161 9
2023/2024943 77 121 258 82 45 175 70 64 16 35 0 0
Totale 2.253